Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
18,766 total articles
Adagene Inc. announced its financial results for the six months ended June 30, 2026, highlighting significant clinical advancements in its lead candidate muzastotug (ADG126), a masked anti-CTLA-4 antibody. The company reported encouraging efficacy and safety data in microsatellite stable colorectal cancer (MSS CRC) and hepatocellular carcinoma (HCC…
Unicycive Therapeutics announced its Q2 2026 financial results and provided a business update highlighting progress toward FDA approval of its lead drug candidate, oxylanthanum carbonate (OLC), for treating hyperphosphatemia in dialysis patients. The FDA has assigned a facility inspection to the third-party manufacturer, a prerequisite for NDA resu…
Polar Power, Inc. announced $7.9 million in revenue from the Pacific Islands since 2024, driven by 333 shipments of DC power and solar-hybrid systems to countries including Papua New Guinea and Fiji. Repeat orders from telecommunications customers indicate growing adoption and reliability of its technology. The company is now expanding into adjacen…
Electra Battery Materials Corporation announced the appointment of Peter Rawlins as its new CFO, effective August 26, 2026, bringing extensive mining finance and capital markets experience. The company reported Q2 2026 financial results showing progress in the construction of North America's first cobalt sulfate refinery in Ontario, with constructi…
Milestone Pharmaceuticals announced Q2 2026 financial results and corporate updates, reporting increased patient and prescriber adoption of its FDA-approved cardiovascular drug CARDAMYST for PSVT, expanded insurance coverage to over 50% of commercially insured lives in the U.S., and initiation of a Phase 3 registrational trial for atrial fibrillati…
Alterity Therapeutics announced the granting of a new U.S. composition of matter patent for its lead clinical drug candidate ATH434. This patent extends protection until at least 2045, significantly increasing ATH434's commercial value and underpinning the planned initiation of Phase 3 trials in Multiple System Atrophy by the end of 2026. The stren…
Kamada Ltd., a global biopharmaceutical company specializing in specialty plasma-derived therapies, announced record-high revenues and adjusted EBITDA for the first half and second quarter of 2026, driven by strong sales growth of its proprietary products like KEDRAB in the U.S., VARIZIG, and HEPAGAM. The company affirmed its 2026 annual financial …
TScan Therapeutics reported second quarter 2026 financial results and corporate updates highlighting the dosing of the first patient in the Phase 3 ALLOHA-2 study evaluating their lead TCR-T therapy candidate TSC-101. Positive initial data from the Phase 1 ALLOHA study validated their commercial-ready manufacturing process. The company has a health…
Perma-Fix Environmental Services, Inc. has been awarded a Master IDIQ subcontract by Hanford Tank Waste Operations & Closure, LLC for the treatment and disposal of pretreated liquid mixed low-level waste from the DOE's Hanford Site. The subcontract is effective from August 2026 with task orders expected to begin in 2027, running through 2041. The w…
Kamada Ltd., a global biopharmaceutical company specializing in specialty plasma-derived therapies, announced that CFO Chaime Orlev will step down on December 31, 2026, to pursue other opportunities. The company is conducting a search for his successor and expects a seamless transition. Kamada continues to focus on growth driven by its commercial p…
Octave Intelligence released its second quarter 2026 financial results, highlighting a 7% year-over-year increase in annualized recurring revenue (ARR) driven by 21% SaaS revenue growth. Despite a 4% decline in total revenue reported year-over-year, recurring revenues grew, and the company generated strong free cash flow of $93 million. The quarter…
Lexeo Therapeutics reported Q2 2026 financials and operational updates, highlighting the initiation of the pivotal SUNRISE-FA 2 trial for LX2006 targeting Friedreich ataxia cardiomyopathy with topline data expected in H2 2027. The company received FDA RMAT designation for LX2020 in PKP2 arrhythmogenic cardiomyopathy, supporting expedited developmen…
Humacyte announced promising interim Phase 3 data for its acellular tissue engineered vessel (ATEV) in female dialysis patients, outperforming the current standard AV fistula, with plans to file a supplemental BLA with the FDA in H2 2026. The FDA accepted an IND for a first-in-human study of Humacyte's coronary tissue engineered vessel (CTEV) for c…
Marex Group Limited reported its preliminary unaudited Q2 2026 financial results showing record revenue of $695.8 million and adjusted profit before tax of $165.9 million, representing 39% and 56% year-on-year growth respectively. The company's diversified platform delivered growth across all business segments including Clearing, Agency and Executi…
Aclarion, Inc. announced a Notice of Allowance from the USPTO for a patent covering their technology to precisely position MR Spectroscopy sampling locations within lumbar discs, enhancing accuracy and efficiency of their Nociscan diagnostic platform for chronic low back pain. This patent expands the company's IP portfolio, aiming to reduce scan va…
Can-Fite BioPharma announced progress in the regulatory status of its lead drug candidates, Namodenoson and Piclidenoson, both in Phase III clinical trials targeting liver cancer (HCC) and moderate-to-severe plaque psoriasis. Namodenoson holds FDA Fast Track and Orphan Drug designations in the US and Europe, providing accelerated pathways toward ma…
Aurora Mobile Limited announced the addition of PixVerse V6, a flagship AI video generation model, to its unified AI media generation platform Modellix. PixVerse V6 delivers production-quality 15-second 1080p videos with synchronized audio and multi-shot scene controls in a single request, intended to streamline content creation for marketing, e-co…
RedCloud Holdings plc announced two Memoranda of Understanding to deploy its AI-powered RAID and CORE engines in collaboration with Dheer Marketing India Pvt. Ltd. and Klakshya Marketing Pvt. Ltd. targeting apparel, footwear, and lifestyle markets in India. The initiative aims to leverage AI for real-time trade data analysis to improve forecasting,…
Fervo Energy reported its Q2 2026 financial and operational results, highlighting its recent public listing on NASDAQ raising $2.2 billion, progress on its enhanced geothermal Cape Station project including mechanical completion of two GeoBlocks and upcoming commissioning, record drilling achievements, and raised development targets to 1.1 GW by 20…
WeRide Inc., a leader in autonomous driving technology, reported impressive financial results for Q2 2026 with total revenue rising 82.2% YoY to RMB231.7 million. The company showcased significant overseas expansion, particularly in Europe and the Middle East, and continued improvements in domestic robotaxi operations. Key technology launches inclu…
Auddia Inc. (NASDAQ: AUUD) has filed its definitive proxy statement with the SEC and scheduled a special shareholder meeting on September 23, 2026, to vote on its proposed merger with Thramann Holdings. This merger will create McCarthy Finney, an AI-focused holding company combining Auddia and three AI native companies: LT350, Influence Healthcare,…
LeonaBio announced that its lead drug candidate, lasofoxifene, will be highlighted in several presentations at Dava Oncology's 4th Summit on Breast Cancer. The presentations will emphasize lasofoxifene's potential as a novel treatment for ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer, including progress in its pivotal Phase 3 EL…
Sutro Biopharma announced favorable early clinical activity of STRO-004 in its Phase 1 trial demonstrating partial responses and a good safety profile. The company is rapidly progressing dose optimization and plans to initiate additional clinical trials of STRO-006 and dual-payload ADC STRO-227 in 2026. Sutro reported solid cash reserves of $164.3 …
SUNation Energy reported its Q2 2026 financial results with a 38% year-over-year decline in consolidated revenue primarily due to the expiration of the federal Section 25D residential solar tax credit. The company focused on cost reductions, balance sheet improvements, and progressed a strategic reverse merger transaction with Suniva, Inc., targeti…
Fusemachines Inc. announced a strategic agreement with South American technology services leader Qintess, who has committed to spend at least $6.5 million on Fusemachines' Agentic AI products and services over the next three years. The partnership aims to integrate Fusemachines' AI technology within Qintess' operations and client offerings, expandi…
